Pharma Deals May Cut Trump MFN Savings by 80% — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration's most-favored nation drug pricing plan could see projected savings slashed by as much as 80% due to secretive deals with more than two dozen pharmaceutical companies, according to a new analysis.
- The approach ties Medicare drug prices to what 19 other wealthy nations pay for the same medicines, with the White House claiming the effort would save $26 billion over several years.
- Two pilot programs — GLOBE for Medicare Part B and GUARD for Medicare Part D — will require drug companies to pay additional rebates if prices exceed the lowest international price among those 19 countries.
- More specific rules for the GLOBE and GUARD programs are due shortly.
Why it matters: If the analysis holds, the White House's headline $26 billion savings projection could shrink to roughly $5 billion — undercutting the administration's flagship drug-cost initiative at a time when Medicare beneficiaries are facing rising prescription prices and the policy's two pilot programs have not yet been finalized.
Ask SkimNews
